CARM
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | 1.07 | $45M | $2M |
| 2025 Q2 | -0.23 | $0 | -$6M |
| 2025 Q1 | -0.22 | $4M | -$10M |
| 2024 Q4 | -0.42 | $4M | -$8M |
| 2024 Q3 | -0.31 | $3M | -$13M |
| 2024 Q2 | -0.27 | $9M | -$16M |
| 2024 Q1 | -0.46 | $3M | -$22M |
| 2023 Q4 | -0.52 | $4M | -$17M |